Biohaven 대차 대조표 상태

재무 상태 기준 확인 4/6

Biohaven 의 총 주주 지분은 $316.0M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $510.5M 및 $194.5M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$378.82m
주식	US$316.01m
총 부채	US$194.52m
총 자산	US$510.52m

최근 재무 상태 업데이트

Recent updates

Biohaven: A Complicated Tale

Oct 11

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Sep 23

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Jul 26

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

재무 상태 분석

단기부채: BHVN 의 단기 자산 ( $440.5M )이 단기 부채( $152.3M ).

장기 부채: BHVN 의 단기 자산( $440.5M )이 장기 부채( $42.2M ).

부채 대 자본 내역 및 분석

부채 수준: BHVN 부채가 없습니다.

부채 감소: BHVN 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BHVN 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 37.9 %의 역사적 비율로 계속 감소할 경우 BHVN 의 현금 활주로는 1년 미만입니다.

Biohaven 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Recent updates

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

New minor risk - Share price stability

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Consensus EPS estimates fall by 23%

Independent Director recently bought US$1.0m worth of stock

Independent Director recently bought US$999k worth of stock

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $230.000037 million.

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Now 21% overvalued after recent price rise

Biohaven Ltd., Annual General Meeting, Apr 30, 2024

Now 21% overvalued after recent price rise

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

New major risk - Financial position

Director exercised options and sold US$460k worth of stock

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Price target increased by 11% to US$33.17

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Price target increased by 7.8% to US$30.00

Price target increased by 7.4% to US$29.00

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Independent Director recently bought US$402k worth of stock

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Biohaven Ltd. Announces Positive Data from its Exploratory Electroencephalogram Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Independent Director recently bought US$922k worth of stock

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Independent Director recently bought US$2.0m worth of stock

New minor risk - Share price stability

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

High number of new and inexperienced directors

Biohaven Ltd: Assessing The Spinoff

Biohaven Non-GAAP EPS of -$1.25

Chairman & CEO recently bought US$2.1m worth of stock

Biohaven Ltd. Advances Development of the MoDE Platform Technology Licensed From Yale University

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기